When Parkinson's disease occurs alongside an anxiety disorder, the clinical picture is more complex than motor symptoms alone. Anxiety — particularly when tied to affective fluctuations — must be addressed as an integral part of treatment planning, not as a secondary concern.
This protocol is specifically for patients with Parkinson's disease who have a concurrent anxiety disorder. The co-occurrence of anxiety, especially when affective fluctuations are present, directly influences therapeutic decisions and the selection of pharmacological options.
The foundation of management is optimising dopaminergic therapy. In patients where anxiety is accompanied by affective fluctuations, a specific category of dopamine agonist may be considered when individualised therapy is feasible. An additional pharmacological option exists for addressing anxiety symptoms directly.